08 Feb 2012
Their study suggests that the novel RWD-domain containing protein RSUME is a new and important player in pituitary tumour pathogenesis. It is overexpressed in human pituitary adenomas and critically regulates HIF-1α expression and VEGF-A production under hypoxia. Through supporting pituitary tumour neovascularisation, RSUME might be critically involved in pituitary adenoma progression. Therefore, it represents a new putative therapeutic target for the development of novel anti-angiogenic treatment concepts of human pituitary tumours. Shan et al. (2012) Endocrine-Related Cancer 19 13-27.
Read the full article at DOI: 10.1530/ERC-11-0211.
NEW Research SIG
07 Jan 2025
ISE selects Bioscientifica as its association management provider
01 Jan 2025
Division Chief of Endocrinology
01 Jan 2025
Society members recognised in New Year Honours List
01 Jan 2025